Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Co., has entered into an agreement with Inovalon, a technology provider of cloud-based platforms for the life sciences.

The agreement utilizes Inovalon and Avalere’s combined platform aimed at supporting greater customer insight, data integration and analytics, and provider and patient-level intervention capabilities. This aims to support outcomes-based contracting and help translate clinical outcomes into real world practice to improve patient clinical care.
 
“The Boehringer, Lilly diabetes alliance is committed to innovation through the discovery and development of treatment options where unmet needs exist, as illustrated by the breakthrough evidence from the landmark EMPA-REG OUTCOME trial which evaluated cardiovascular outcomes in adults with type 2 diabetes,” said Christine Marsh, vice president, Market Access, Boehringer Ingelheim. “We are excited to be working with the combined capabilities of Inovalon and Avalere, and believe that they will support us in our goal of translating clinical outcomes into real world practice to ultimately improve patient care.”